An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH

Study LTI-401 is an open-label, multicenter study which will evaluate the safety and tolerability of LIQ861 in subjects who have WHO Group 1 \& 3 PH.

NCT Number	NCT06129240
Lead Sponsor	Liquidia Technologies, Inc.
Conditions	Pulmonary Hypertension, Interstitial Lung Disease
Enrollment	80 participants
Start Date	2023-12-28
Primary Completion	2027-07-31 (estimated)
Study Completion	2028-02-08 (estimated)
Updated on ClinicalTrials.gov	2026-06-26